Clinical Cancer Research, Vol 2, Issue 9 1591-1599, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up

O Caffo, C Doglioni, S Veronese, M Bonzanini, A Marchetti, F Buttitta, P Fina, R Leek, L Morelli, PD Palma, AL Harris and M Barbareschi
Departments of Histopathology, S. Chiara Hospital, Largo Medaglie d'Oro, 38100, Trento, Italy.

p21 protein (p21) inhibitor of cyclin-dependent kinases is a critical downstream effector in the p53-specific pathway of growth control and can also be induced by p53-independent pathways in relation to terminal differentiation. We investigated p21 immunoreactivity in 261 breast carcinomas (141 node negative and 120 node positive) with long-term follow-up (median, 73 months; range, 37-119). p21 was seen in 214 (82%) infiltrating tumors, staining was nuclear and heterogeneous, and the p21 labeling index ranged from 0 to 90%. Sixty-eight (32%) patients showed p21 overexpression (>10% of reactive tumor cells). p21 overexpression was associated with large tumor size, positive nodal status, high histological grade, and high mitotic count and was related to short disease-free survival (DFS) in the whole series of patients (P = 0.04), in the node-negative subgroup (P = 0.004), and in the group of patients who did not undergo systemic adjuvant therapy (P = 0.003). In patients treated with systemic adjuvant therapy, bivariate analysis of the combined p21 and p53 phenotypes showed that p21+/p53+ tumors were associated with long DFS and overall survival (OS), whereas p21-/p53+ tumors had the worst prognosis. In treated patients, multivariate analysis showed that the p21-/53+ phenotype was independently associated with short DFS and OS. Our present data support the hypothesis that p21/p53 heterogeneous expression may be of clinical relevance for the therapeutic response to chemotherapy/hormonotherapy. The p21-/p53+ phenotype could correspond to a situation where p53 overexpression really reflects complete abrogation of p53 function. These cases with disrupted p53 function should have impaired the G1 checkpoint and may not be able to activate the apoptotic cascade in response to DNA-damaging drugs.

This article has been cited by other articles:

				M. Maynadier, J.-M. Ramirez, A.-M. Cathiard, N. Platet, D. Gras, M. Gleizes, M. S. Sheikh, P. Nirde, and M. Garcia Unliganded estrogen receptor {alpha} inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21WAF1) FASEB J, March 1, 2008; 22(3): 671 - 681. [Abstract] [Full Text] [PDF]

				M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]

				A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59. [Abstract] [Full Text] [PDF]

				M J Pellikainen, T T Pekola, K M Ropponen, V V Kataja, J K Kellokoski, M J Eskelinen, and V-M Kosma p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis J. Clin. Pathol., March 1, 2003; 56(3): 214 - 220. [Abstract] [Full Text] [PDF]

				X. Xie, O. P. F. Clausen, and M. Boysen Prognostic Significance of p21WAF1/CIP1 Expression in Tongue Squamous Cell Carcinomas Arch Otolaryngol Head Neck Surg, August 1, 2002; 128(8): 897 - 902. [Abstract] [Full Text] [PDF]

				G. Curigliano, M. Colleoni, G. Renne, G. Mazzarol, R. Gennari, G. Peruzzotti, F. de Braud, C. Robertson, E. Maiorano, P. Veronesi, et al. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay Ann. Onc., June 1, 2002; 13(6): 895 - 902. [Abstract] [Full Text] [PDF]

				C. Keshava, B. L. Frye, M. S. Wolff, E. C. McCanlies, and A. Weston Waf-1 (p21) and p53 Polymorphisms in Breast Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 127 - 130. [Abstract] [Full Text]

				U-J Gohring, A Bersch, M Becker, W Neuhaus, and T Schondorf p21waf correlates with DNA replication but not with prognosis in invasive breast cancer J. Clin. Pathol., November 1, 2001; 54(11): 866 - 870. [Abstract] [Full Text] [PDF]

				M J Schwerer, A Sailer, K Kraft, K Baczako, and H Maier Patterns of p21waf1/cip1 expression in non-papillomatous nasal mucosa, endophytic sinonasal papillomas, and associated carcinomas J. Clin. Pathol., November 1, 2001; 54(11): 871 - 876. [Abstract] [Full Text] [PDF]

				M. Migaldi, A. Sgambato, L. Garagnani, R. Ardito, P. Ferrari, Carmela De Gaetani, A. Cittadini, and G. P. Trentini Loss of p21Waf1 Expression Is a Strong Predictor of Reduced Survival in Primary Superficial Bladder Cancers Clin. Cancer Res., August 1, 2000; 6(8): 3131 - 3138. [Abstract] [Full Text]

				I. Osman, M. Drobnjak, M. Fazzari, J. Ferrara, H. I. Scher, and C. Cordon-Cardo Inactivation of the p53 Pathway in Prostate Cancer: Impact on Tumor Progression Clin. Cancer Res., August 1, 1999; 5(8): 2082 - 2088. [Abstract] [Full Text] [PDF]